Data cannot be shared publicly because of ethical restrictions. Data are available from the APCAPs cohort (contact via <http://apcaps.lshtm.ac.uk/>) for researchers who meet the criteria for access to confidential data.

Introduction {#sec007}
============

Cardiovascular disease is the leading cause of death and disability worldwide. The striking rise in the prevalence of cardiovascular disease in many low- and middle-income countries (LMICs), notably South Asia, is unexplained by population ageing and lifestyle changes associated with economic transition \[[@pmed.1003183.ref001],[@pmed.1003183.ref002]\]. Social disadvantage in the early years of life appears to account for some of the increase in risk, but the biological mechanisms for this association are unknown \[[@pmed.1003183.ref003]\]. A series of reports linking low birth weight to cardiovascular disease, as well as supportive animal models, have led to the hypothesis that undernutrition during intrauterine life and early childhood (critical or sensitive period) may have long-lasting effects on the future risk of cardiovascular disease through persistence of metabolic and physiological adaptations (Developmental Origins of Health and Disease Hypothesis) \[[@pmed.1003183.ref004]--[@pmed.1003183.ref007]\]. However, most of these studies were conducted in high-income countries, where maternal smoking during pregnancy is a more common cause of low birth weight than undernutrition, leading other researchers to suggest that the observed associations may be confounded by behavioural risks associated with persistent social disadvantage \[[@pmed.1003183.ref008],[@pmed.1003183.ref009]\].

Few studies have been able to test this hypothesis in a trial setting, and the findings have been inconsistent \[[@pmed.1003183.ref010]--[@pmed.1003183.ref012]\]. We assessed cardiovascular disease risk factors among a cohort of young adults who were born during a trial of protein-calorie supplemental nutrition offered to pregnant women and young children in an area with prevalent undernutrition. We hypothesised that supplemental nutrition during pregnancy and early childhood would be associated with lower levels of cardiovascular disease risk factors in young adulthood.

Methods {#sec008}
=======

The study is reported in accordance with the CONSORT guideline ([S1 CONSORT checklist](#pmed.1003183.s001){ref-type="supplementary-material"}). The Hyderabad Nutrition Trial (1987--1990) was a community-based nonrandomised controlled intervention trial conducted in 29 villages of Ranga Reddy district in Telangana state, India \[[@pmed.1003183.ref012],[@pmed.1003183.ref013]\]. It evaluated India's Integrated Child Development Services (ICDS) scheme, which is a long-standing scheme aimed at improving child growth and development through integrated provision of food supplementation, anaemia control, immunisation, education, and basic healthcare to pregnant and lactating women and children up to 6 years \[[@pmed.1003183.ref013]\]. Using the opportunity afforded by the gradual rollout of this nationwide scheme during the 1980s and 1990s, the National Institute of Nutrition of India conducted the trial to assess the effect of food supplementation in pregnancy on the offspring's birth weight. A cluster of villages was chosen from two adjacent administrative areas (called 'blocks'): one with the ICDS scheme in place (intervention arm) and the other awaiting implementation at that time (control arm) ([Fig 1](#pmed.1003183.g001){ref-type="fig"}). As the 100 or so villages in each of the two blocks were spread over an unfeasibly large area for data collection, contiguous villages surrounding the geographic centre of each block were selected to make up the planned sample size of 30,000 total population in each block. This resulted in 15 intervention and 14 control villages geographically separated by uninvolved villages. The food supplement ('upma', a local food prepared from corn-soya blend and soya bean oil) was offered daily to women throughout pregnancy and lactation (2.51 MJ of energy and 20--25 g of protein daily) and children below the age of 6 years (1.25 MJ and 8--10 g protein daily). A total of 2,964 birth weights were recorded within 48 hours of delivery with an infant beam balance with an accuracy of 20 g (John Chatillon & Sons, NY). The mean birth weight of children born in the intervention area was higher than control (2,655 g versus 2,594 g), with a mean difference of 61 g (95% confidence interval 18 to 104; *p* = 0.007) \[[@pmed.1003183.ref012],[@pmed.1003183.ref014]\]. The trial was not registered, as it was not standard practice to register community trials at that time. The trial families were recontacted in 2003--2005; offspring born in the trial (*N* = 2,601) and their parents and siblings constitute the intergenerational Andhra Pradesh Children and Parents study (APCAPs) \[[@pmed.1003183.ref015]\].

![Map of APCAPs villages.\
Village urbanisation measured by nighttime light intensity assessed by remote sensing. Background maps were rendered by the authors using R, based on geodata made available by Geofabrik.de and OpenStreetMap.org, under the Open Database License (<https://opendatacommons.org/licenses/odbl/1.0/>). APCAPs, Andhra Pradesh Children and Parents study.](pmed.1003183.g001){#pmed.1003183.g001}

The offspring born during the trial have been followed up three times: first follow-up in 2003--2005 (mean age 16 years; *N* = 1,165), second follow-up in 2009--2010 (mean age of 20 years; *N* = 1,446), and third follow-up in 2010--2012 (mean age of 22 years; *N* = 1,360) ([Fig 2](#pmed.1003183.g002){ref-type="fig"}). Fewer participants were invited for examination at the first follow-up (*N* = 1,492, 78% response) due to resource constraints (it was a PhD project funded by a small travel award); priority was given to those on whom additional data on compliance and growth were thought to be available at that time. At the time of the first follow-up at age 16 years, children born in the intervention villages were found to be taller and had lower levels of arterial stiffness and insulin resistance, suggesting lower risk of cardiovascular disease \[[@pmed.1003183.ref012]\]. In this report, we present the findings from the second and third follow-ups of trial offspring. The third follow-up was conducted primarily to extend the study to parents and siblings of the trial offspring; however, the trial offspring were also offered the opportunity to take part again, resulting in the close timing of the two surveys. Given the close timing and a substantial number of nonoverlapping participants, we combined data from the two follow-ups to maximise study power and reduce selection bias. Where individual participant data were available from both surveys, we used data from the later survey wave because our primary interest was in cardiovascular risk in adulthood. This resulted in 1,826 participants at a mean age of 21.6 years (62% males). Since the first follow-up, the peri-urban study villages have experienced rapid unplanned urbanisation, which we quantified using data from remote sensing and took into account in our analyses (see details later) \[[@pmed.1003183.ref016]\]. Ethical approvals for second and third follow-ups of the cohort were obtained from the Public Health Foundation of India, New Delhi, India; National Institute of Nutrition, Hyderabad, India; University of Bristol, Bristol, United Kingdom; and the London School of Hygiene & Tropical Medicine (LSHTM), London, UK. Verbal permissions were taken from heads and governing committees of the villages. Written informed consent (or witnessed thumbprint if illiterate) for inclusion in the study was obtained from each participant prior to enrolment.

![Flowchart of APCAPs study participants at the first, second, and third follow-ups, 2003--2012.\
APCAPs, Andhra Pradesh Children and Parents study.](pmed.1003183.g002){#pmed.1003183.g002}

Measurements {#sec009}
------------

The study participants were interviewed and examined by trained observers using standardised methods, which have been described in detail previously (full protocol in [S1 Text](#pmed.1003183.s002){ref-type="supplementary-material"}) \[[@pmed.1003183.ref015]\]. No change was made to the study protocol after the start of the study. Sociodemographic and lifestyle (i.e., tobacco and alcohol use) data were collected using standard questions from India's Third National Family Health Survey \[[@pmed.1003183.ref016]\]. Socioeconomic position was assessed using a subset of 14 questions (out of 29) of the Standard of Living Index (SLI) and applying the prescribed weights; a higher score indicates a higher socioeconomic position. A semiquantitative food frequency questionnaire coupled with customised nutrient databases was used to estimate average daily salt and fat consumption and energy intake; its validation against multiple weighed 24-hour recalls in this setting has been published \[[@pmed.1003183.ref017]\]. Physical activity was assessed using a validated questionnaire (activities over the past week), which was used to derive metabolic equivalent tasks (METs; expressed in hours/day) and time spent sedentary (minutes/day); its validation against triaxial accelerometers in this setting has been published \[[@pmed.1003183.ref018]\]. Anthropometric assessments were carried out using standard protocols \[[@pmed.1003183.ref015]\]. Weight was measured with a digital weighing scale (SECA, [www.seca.com](http://www.seca.com)) and standing height with a plastic stadiometer (Leicester measure; Chasmors, London, UK). Waist circumference was measured using a non-stretch metallic tape at the narrowest point of the abdomen between the ribs and the iliac crest. Anthropometric measurements were taken twice and averaged for analyses; where the difference between readings was more than the acceptable level (5 mm for height, 0.5 kg for weight, and 1 cm for waist circumference), a third reading was taken.

Vascular assessments were carried out using recommended guidelines, as described previously \[[@pmed.1003183.ref019]\]. Blood pressure was measured on the right arm in the supine position using a validated oscillometric device (Model M5-I; Omron, Matsusaka, Japan) with appropriate cuff size. Arterial stiffness (augmentation index and aortic pulse wave velocity) and central systolic blood pressure were assessed using a Vicorder device (Skidmore Medical, Bristol, UK); higher values for arterial stiffness measures indicate stiffer arteries and increased vascular age. Blood pressure cuffs were placed around the neck (at the level of carotid artery) and upper thigh and inflated to 60 mm Hg before recording the waveforms. Three consecutive measurements of blood pressure and arterial stiffness were taken after a rest of five minutes (one minute of rest between readings) and then averaged for analyses. Carotid intima media thickness was measured on the near wall of the distal common carotid artery (right-hand side) using a B-mode ultrasound (Ethiroli Tiny 16a; Surabhi Biomedical Instrumentation, Chennai, India). Images were normalised before analyses by Carotid Plaque Texture Analysis software (LifeQ, Engomi, Cyprus). Two measurements of carotid intima media thickness were taken by separate operators and averaged for analysis.

Venous blood samples were collected after an overnight fast. Glucose was assayed on the same day using the oxidase-peroxidase enzymatic (GOD-PAP) method (reagents supplied by Randox Laboratory, Crumlin city, UK). An enzymatic colorimetric method was used to assay total cholesterol, triglycerides, and serum high-density lipoprotein cholesterol (HDL-C). Lipids and insulin assays were carried out using reagents supplied by Roche Diagnostics, Basel, Switzerland. Serum insulin was assayed on an e-411 autoanalyser using an electrochemiluminescence immunoassay. The quality of biochemical assays was assured through internal controls and external assurance arrangements with Randox International Quality Assessment Scheme (lipids) and UK National External Quality Control Assessment Service (insulin). Intra- and inter-assay coefficients of variation were ≤3% and ≤5%, respectively, for all assays.

Quality of clinical measurements was ensured through rigorous protocols, regular standardisation of equipment, and teams to detect any drifts over time \[[@pmed.1003183.ref015]\]. Reproducibility of measurements was evaluated by repeat measurements on a 5% random subsample; the intraclass correlation coefficients were \>0.98 for anthropometric measurements, \>0.85 for vascular measurements, and \>0.94 for biochemical assays.

Village urbanisation was quantified using nighttime light intensity (NTLI), a data product derived from satellite sensors that capture visible near-infrared emissions from the earth's surface, which has been used to measure urbanisation and predict cardio-metabolic risk in several settings, including APCAPs cohort participants \[[@pmed.1003183.ref019],[@pmed.1003183.ref020]\]. Geocoded village boundaries were applied to 2012 data from the Defense Meteorological Satellite Program (Operational Linescan System) accurate to a 1-km resolution, such that NTLI values represent emissions from the village areas only.

Statistical analyses {#sec010}
--------------------

We compared values of cardiovascular risk factors in intervention and control villages using a linear regression model and assessed the effect of the intervention using beta coefficients. We fitted a random intercept at both village and household levels, to allow for clustering of outcomes. Adiposity was estimated by body mass index (BMI); pulse pressure as difference between systolic and diastolic blood pressure; low-density lipoprotein (LDL) cholesterol using the Friedewald-Fredrickson formula; and insulin resistance by homeostatic model assessment-insulin resistance (HOMA-IR). We log-transformed the following variables prior to analyses to achieve a more Gaussian distribution: triglycerides, insulin, and HOMA-IR. Values of insulin were standardised across the two waves in order to allow for differences in assay techniques. Analyses were carried out using the 'intention-to-treat' principle, comparing risk factors of children born in the intervention and control areas. In view of the nonrandomised trial design and varying urbanisation of the study villages over the long-term follow-up, we fitted three predefined models to incrementally adjust for potential differences in sociodemographic and lifestyle factors that could influence the levels of cardiovascular risk factors: model 1 was adjusted for age and sex; model 2 was additionally adjusted for socioeconomic position and village urbanisation; and model 3 was further adjusted for lifestyle factors, including tobacco and alcohol use, fat and salt consumption, and physical activity level and sedentariness. We used formal tests of interactions to examine whether the effects of membership of treatment arm on outcomes were modified by age (split by median age of 22 years), sex, village urbanisation (thirds) and current obesity (split by median of 20 kg/m^2^). To assess the impact of potential difference in samples between first and second or third follow-ups, we restricted the analyses to those who also presented at the first follow-up (sensitivity analyses).

Results {#sec011}
=======

A total of 1,826 (70% of cohort) participants were examined at least once between 2009 and 2012, of which 881 were also examined during the first follow-up in 2003--2005. In comparisons of cardiovascular risk factor data collected in the first follow-up, those who took part in the second or third follow-ups were broadly similar to those who took part in the first follow-up alone ([Table 1](#pmed.1003183.t001){ref-type="table"}).

10.1371/journal.pmed.1003183.t001

###### Participant characteristics in 2003--2005 split by presentation in 2009--2012.

![](pmed.1003183.t001){#pmed.1003183.t001g}

  Characteristics                   Absent in 2009--2012 (*n* = 284)   Present in 2009--2012 (*n* = 881)   *p*-Value
  --------------------------------- ---------------------------------- ----------------------------------- -----------
  **ALL PARTICIPANTS**                                                                                     
  From intervention village         154 (58.6%)                        475 (57.9%)                         0.84
  Age (years)                       15 (1)                             15 (1)                              0.94
  Male sex                          60 (22.8%)                         529 (64.4%)                         \<0.001
  Village urbanisation score                                                                               0.96
   Least urbanised third            71 (27.1%)                         233 (28.4%)                         
   Middle third                     91 (34.7%)                         277 (33.8%)                         
   Most urbanised third             100 (38.2%)                        310 (37.8%)                         
  SLI score                                                                                                \<0.001
   Bottom third                     57 (21.5%)                         300 (36.6%)                         
   Middle third                     90 (34.0%)                         263 (31.3%)                         
   Top third                        118 (44.5%)                        257 (31.3%)                         
  Occupation                                                                                               \<0.001
   Unemployed                       25 (9.2%)                          60 (7.2%)                           
   Student                          203 (74.4%)                        703 (83.9%)                         
   Employed                         45 (16.5%)                         75 (8.9%)                           
  Height (cm)                       149.1 (14.1)                       150.1 (7.6)                         0.18
  BMI (kg/m^2^)                     20.7 (4.4)                         20.7 (4.2)                          0.85
  Systolic blood pressure (mm Hg)   108.3 (9.2)                        109.2 (10.5)                        0.20
  Total cholesterol (mmol/L)        3.6 (0.7)                          3.4 (0.7)                           \<0.001
  Insulin (mU/L)                    19.0 (12.1 to 26.4)                16.8 (10.9 to 24.9)                 0.01
  Augmentation index (%)            5.0 (−2.5 to 10.5)                 5.0 (−3.5 to 11.0)                  0.67
  **CONTROL PARTICIPANTS**                                                                                 
  From intervention village         0 (0.0%)                           0 (0.0%)                            
  Age (years)                       15 (1)                             15 (1)                              0.28
  Male sex                          28 (25.7%)                         225 (65.0%)                         \<0.001
  Village urbanisation score                                                                               0.001
   Least urbanised third            39 (35.8%)                         141 (40.8%)                         
   Middle third                     45 (41.3%)                         82 (23.7%)                          
   Most urbanised third             25 (22.9%)                         123 (35.5%)                         
  SLI score                                                                                                \<0.001
   Bottom third                     19 (18.4%)                         127 (39.9%)                         
   Middle third                     39 (37.9%)                         102 (32.1%)                         
   Top third                        45 (43.7%)                         89 (28.0%)                          
  Occupation                                                                                               0.06
   Unemployed                       10 (9.7%)                          34 (10.6%)                          
   Student                          75 (72.8%)                         258 (80.4%)                         
   Employed                         18 (17.5%)                         29 (9.0%)                           
  Height (cm)                       149.7 (6.2)                        150.2 (6.0)                         0.56
  Body mass index (kg/m^2^)         20.8 (5.0)                         20.8 (4.1)                          1.00
  Systolic blood pressure (mm Hg)   109.6 (8.7)                        109.3 (10.2)                        0.80
  Total cholesterol (mmol/L)        3.5 (0.6)                          3.4 (0.7)                           0.036
  Insulin (mU/L)                    21.3 (14.1 to 30.8)                18.1 (12.5 to 26.9)                 0.038
  Augmentation index (%)            6.3 (2.5 to 10.3)                  6.5 (−1.5 to 12.0)                  0.73
  **INTERVENTION PARTICIPANTS**                                                                            
  From intervention village         154 (100.0%)                       475 (100.0%)                        
  Age (years)                       15 (1)                             15 (1)                              0.41
  Male sex                          32 (20.8%)                         304 (64.0%)                         \<0.001
  Level of urbanisation (thirds)                                                                           0.042
   Least urbanised                  32 (20.9%)                         92 (19.4%)                          
   Middle third                     46 (30.1%)                         195 (41.1%)                         
   Most urbanised                   75 (49.0%)                         187 (39.5%)                         
  SLI score                                                                                                0.002
   Bottom third                     30 (21.0%)                         156 (32.5%)                         
   Middle third                     45 (31.5%)                         137 (30.9%)                         
   Top third                        68 (47.6%)                         150 (33.9%)                         
  Occupation                                                                                               0.036
   Unemployed                       12 (8.0%)                          22 (4.8%)                           
   Student                          116 (77.3%)                        394 (86.2%)                         
   Employed                         22 (14.7%)                         41 (9.0%)                           
  Height (cm)                       148.7 (17.2)                       150.0 (8.6)                         0.24
  Body mass index (kg/m^2^)         20.7 (4.1)                         20.6 (4.3)                          0.79
  Systolic blood pressure (mm Hg)   107.4 (9.4)                        109.2 (10.7)                        0.067
  Total cholesterol (mmol/L)        3.7 (0.7)                          3.4 (0.7)                           \<0.001
  Insulin (mU/L)                    16.7 (11.3 to 25.2)                15.6 (10.2 to 22.3)                 0.090
  Augmentation index (%)            2.5 (−5.3 to 11.3)                 3.0 (−5.0 to 10.5)                  0.82

Data shown are number (%), mean (standard deviation), or median (interquartile range).

Data shown are only for those who took part in the 2003--2005 follow-up.

Abbreviations: BMI, body mass index; SLI, Standard of Living Index

The mean age of the participants was 21.6 years (62% males) ([Table 2](#pmed.1003183.t002){ref-type="table"}). Just over half of the participants were employed and about a quarter were in full-time education. About 10% consumed tobacco and mean BMI was 20 (SD 3.2) kg/m^2^. The village urbanisation score was clearly different between trial arms: about 20% of the intervention arm participants lived in the least urbanised third of villages, as opposed to 44% in the control arm (3 villages in intervention arm and 7 villages in control arm belonged to the least urbanised thirds category). Missing data, notably for arterial stiffness and carotid intima media thickness measurements (relatively more due to greater time commitment required from the participants), were evenly distributed across the trial arms. There were no differences in the levels of cardiovascular risk factors between trial arms ([Table 3](#pmed.1003183.t003){ref-type="table"}). There was no strong evidence for effect modification by age, sex, village urbanisation and current obesity (see [S1](#pmed.1003183.s003){ref-type="supplementary-material"}, [S2](#pmed.1003183.s004){ref-type="supplementary-material"}, [S3](#pmed.1003183.s005){ref-type="supplementary-material"} and [S4](#pmed.1003183.s006){ref-type="supplementary-material"} Tables). In sensitivity analyses restricted to participants who were also examined in the first follow-up, results were broadly similar; although borderline effects of intervention on some outcomes (height, augmentation index, and HOMA score) were noted in models adjusted for socioeconomic position and urbanisation, their confidence intervals overlapped with those for effect estimates for the full cohort ([Table 4](#pmed.1003183.t004){ref-type="table"}).

10.1371/journal.pmed.1003183.t002

###### Distribution of cardiovascular risk factors of APCAPs participants in 2009--2012.

![](pmed.1003183.t002){#pmed.1003183.t002g}

  Risk factors                        Missing data[\*](#t002fn002){ref-type="table-fn"} (%)   Intervention (*n* = 949)   Control (*n* = 877)   *p*-Value
  ----------------------------------- ------------------------------------------------------- -------------------------- --------------------- -----------
  Age (years)                         0.0%                                                    21.7 (1.8)                 21.6 (1.9)            0.79
  Male                                0.0%                                                    580 (61.1%)                530 (60.4%)           0.78
  Village urbanisation score          0.4%                                                                                                     0.32
   Least urbanised third                                                                      185 (19.7%)                381 (43.4%)           
   Middle third                                                                               400 (42.5%)                202 (23.0%)           
   Most urbanised third                                                                       356 (37.8%)                294 (33.5%)           
  Occupation                          0.0%                                                                                                     0.26
   Unemployed                                                                                 209 (22.0%)                188 (21.4%)           
   Student                                                                                    259 (27.3%)                202 (23.0%)           
   Employed                                                                                   481 (50.7%)                487 (55.5%)           
  SLI score                           0.5%                                                                                                     0.65
   Bottom third                                                                               208 (22.0%)                215 (24.6%)           
   Middle third                                                                               336 (35.6%)                300 (34.4%)           
   Top third                                                                                  400 (42.4%)                358 (41.0%)           
  Tobacco use (current/former)        0.1%                                                    117 (12.3%)                90 (10.3%)            0.18
  Alcohol use (daily)                 0.1%                                                    25 (2.6%)                  22 (2.5%)             0.82
  Time spent sedentary (hours/day)    1.4%                                                    5.5 (3.6 to 7.9)           5.6 (3.5 to 8.5)      0.95
  Physical activity (MET-hours/day)   1.5%                                                    36.4 (34.1 to 39.0)        36.3 (34.0 to 39.6)   0.44
  Salt consumption (g/day)            0.2%                                                    2.0 (1.7 to 2.3)           2.0 (1.7 to 2.2)      0.34
  Fat consumption (% energy intake)   0.2%                                                    18.8 (5.4)                 18.6 (5.5)            0.51
  Height (mm)                         0.0%                                                    1616.6 (90.3)              1614.8 (90.4)         0.73
  BMI (kg/m^2^)                       0.0%                                                    20.1 (3.3)                 20.1 (3.1)            0.44
  Waist circumference (mm)            0.2%                                                    691.7 (86.6)               693.5 (81.6)          0.43
  Systolic blood pressure (mm Hg)     0.1%                                                    115.2 (10.4)               114.2 (10.0)          0.23
  Diastolic blood pressure (mm Hg)    0.1%                                                    73.5 (9.7)                 72.2 (9.5)            0.088
  Pulse pressure (mm Hg)              0.1%                                                    41.6 (6.2)                 42.0 (6.3)            0.45
  Augmentation index (%)              26.1%                                                   12.9 (7.1)                 14.5 (7.5)            0.086
  Central systolic BP (mm Hg)         22.0%                                                   106.4 (9.4)                106.9 (9.6)           0.48
  Pulse wave velocity (m/sec)         13.7%                                                   6.0 (0.7)                  5.9 (0.6)             0.23
  Carotid IMT (mm)                    33.1%                                                   0.55 (0.11)                0.56 (0.12)           0.75
  Total cholesterol (mmol/L)          1.0%                                                    4.1 (1.0)                  4.0 (0.8)             0.28
  LDL cholesterol (mmol/L)            1.4%                                                    2.4 (0.8)                  2.3 (0.7)             0.12
  HDL cholesterol (mmol/L)            1.0%                                                    1.1 (0.3)                  1.1 (0.3)             0.56
  Triglycerides (mmol/L)              1.0%                                                    1.1 (0.8 to 1.4)           1.0 (0.8 to 1.4)      0.41
  Fasting glucose (mmol/L)            1.0%                                                    4.9 (4.5 to 5.2)           4.8 (4.5 to 5.1)      0.94
  Insulin (mU/L)                      1.4%                                                    6.2 (4.0 to 9.5)           5.8 (3.6 to 8.9)      0.49
  HOMA-IR                             1.4%                                                    1.2 (0.7 to 1.9)           1.1 (0.7 to 1.7)      0.64

Data shown are number (%), mean (standard deviation), or median (interquartile range).

\*No significant differences (at *p* \< 0.05) in percent missing data between trial arms.

Abbreviations: APCAPs, Andhra Pradesh Children and Parents study; BMI, body mass index; BP, blood pressure; HDL, is high-density lipoprotein; HOMA-IR, homeostatic model assessment-insulin resistance; IMT, is intima-media thickness; LDL, low-density lipoprotein; MET, metabolic equivalent task; SLI, Standard of Living Index

10.1371/journal.pmed.1003183.t003

###### Multivariable association between supplemental nutrition and cardiovascular risk factors of APCAPs participants in 2009--2012.
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  Outcome                       *N* with data   Model 1                 Model 2   Model 3                                                 
  ----------------------------- --------------- ----------------------- --------- ----------------------- ------- ----------------------- -------
  Height (mm)                   1,783           1 (−5 to 8)             0.70      2 (−5 to 8)             0.63    1 (−5 to 7)             0.70
  BMI (kg/m^2^)                 1,783           −0.18 (−0.65 to 0.29)   0.45      −0.33 (−0.75 to 0.09)   0.12    −0.35 (−0.76 to 0.06)   0.093
  Waist circumference (mm)      1,779           −5 (−15 to 6)           0.40      −8 (−17 to 1)           0.100   −9 (−18 to 1)           0.065
  Systolic BP (mm Hg)           1,782           1.0 (−0.3 to 2.2)       0.13      0.5 (−0.6 to 1.6)       0.34    0.5 (−0.6 to 1.6)       0.36
  Diastolic BP (mm Hg)          1,782           1.2 (−0.1 to 2.5)       0.075     0.8 (−0.2 to 1.7)       0.10    0.7 (−0.2 to 1.6)       0.12
  Central systolic BP (mm Hg)   1,395           −0.1 (−1.2 to 1.0)      0.88      −0.2 (−1.2 to 0.9)      0.73    −0.2 (−1.2 to 0.8)      0.72
  Pulse pressure (mm Hg)        1,782           −0.28 (−0.83 to 0.26)   0.31      −0.15 (−0.70 to 0.39)   0.58    −0.13 (−0.68 to 0.42)   0.65
  Augmentation index (%)        1,322           −1.1 (−2.6 to 0.3)      0.12      −1.1 (−2.5 to 0.3)      0.12    −1.2 (−2.6 to 0.2)      0.097
  Pulse wave velocity (m/s)     1,542           0.05 (−0.03 to 0.13)    0.25      0.03 (−0.04 to 0.10)    0.39    0.02 (−0.04 to 0.09)    0.48
  Carotid IMT (mm)              1,194           0.01 (−0.02 to 0.03)    0.62      0.01 (−0.01 to 0.03)    0.32    0.01 (−0.01 to 0.03)    0.36
  Total cholesterol (mmol/L)    1,764           0.12 (−0.08 to 0.32)    0.23      0.07 (−0.13 to 0.27)    0.48    0.06 (−0.13 to 0.26)    0.52
  LDL cholesterol (mmol/L)      1,756           0.13 (−0.02 to 0.28)    0.089     0.06 (−0.07 to 0.20)    0.36    0.06 (−0.07 to 0.19)    0.37
  HDL cholesterol (mmol/L)      1,764           −0.02 (−0.09 to 0.05)   0.66      0.01 (−0.06 to 0.07)    0.88    0.00 (−0.06 to 0.07)    0.89
  Log triglycerides (mmol/L)    1,763           0.03 (−0.03 to 0.08)    0.34      0.02 (−0.04 to 0.07)    0.53    0.02 (−0.04 to 0.07)    0.58
  Fasting glucose (mmol/L)      1,763           −0.02 (−0.11 to 0.08)   0.08      −0.02 (−0.10 to 0.06)   0.57    −0.03 (−0.11 to 0.05)   0.49
  Log insulin (mU/L)            1,756           0.04 (−0.12 to 0.21)    0.73      −0.05 (−0.18 to 0.08)   0.48    −0.05 (−0.18 to 0.08)   0.43

Model 1 is age and sex adjusted.

Model 2 is further adjusted for socioeconomic position and village urbanisation.

Model 3 is adjusted for variables in model 2 plus behavioural risk factors (tobacco and alcohol use; salt and fat consumption; and physical activity level and sedentariness).

Abbreviations: APCAPs, Andhra Pradesh Children and Parents study; BMI, body mass index; BP, blood pressure, HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment-insulin resistance; IMT, intima-media thickness; LDL, low-density lipoprotein; β (95% CI), beta coefficient and 95% confidence interval

10.1371/journal.pmed.1003183.t004

###### Multivariable association between supplemental nutrition and cardiovascular risk factors in 2009--2012 in APCAPs participants who also presented in 2003--2005.

![](pmed.1003183.t004){#pmed.1003183.t004g}

  Outcome                       *N* with data   Model 1                 Model 2   Model 3                                                   
  ----------------------------- --------------- ----------------------- --------- ------------------------ ------- ------------------------ -------
  Height (mm)                   863             6 (−2 to 14)            0.12      7 (−1 to 15)             0.095   7 (−1 to 15)             0.089
  BMI (kg/m^2^)                 863             −0.43 (−0.90 to 0.05)   0.080     −0.50 (−0.94 to −0.06)   0.027   −0.51 (−0.98 to −0.05)   0.031
  Waist circumference (mm)      862             −9 (−21 to 3)           0.13      −11 (−21 to −0)          0.044   −11 (−22 to −0)          0.043
  Systolic BP (mm Hg)           862             0.4 (−1.1 to 1.8)       0.63      0.1 (−1.3 to 1.4)        0.94    0.0 (−1.3 to 1.4)        0.95
  Diastolic BP (mm Hg)          862             0.8 (−0.4 to 2.0)       0.20      0.4 (−0.9 to 1.6)        0.56    0.3 (−1.0 to 1.5)        0.69
  Central systolic BP (mm Hg)   691             −0.8 (−2.1 to 0.6)      0.26      −0.7 (−2.1 to 0.7)       0.30    −0.7 (−2.1 to 0.7)       0.32
  Pulse pressure (mm Hg)        862             −0.4 (−1.1 to 0.4)      0.32      −0.3 (−1.0 to 0.5)       0.49    −0.2 (−0.9 to 0.6)       0.66
  Augmentation index (%)        663             −2.2 (−3.7 to −0.7)     0.005     −2.3 (−3.8 to −0.8)      0.002   −2.3 (−3.7 to −0.8)      0.002
  Pulse wave velocity (m/s)     767             0.03 (−0.08 to 0.14)    0.61      0.02 (−0.08 to 0.12)     0.74    0.01 (−0.09 to 0.10)     0.90
  Carotid IMT (mm)              585             −0.00 (−0.03 to 0.02)   0.70      −0.00 (−0.02 to 0.02)    0.99    0.00 (−0.02 to 0.02)     0.96
  Total cholesterol (mmol/L)    855             0.08 (−0.14 to 0.30)    0.49      0.02 (−0.20 to 0.23)     0.88    0.00 (−0.21 to 0.22)     0.96
  LDL cholesterol (mmol/L)      852             0.07 (−0.11 to 0.25)    0.42      −0.02 (−0.17 to 0.13)    0.80    −0.02 (−0.17 to 0.12)    0.75
  HDL cholesterol (mmol/L)      855             −0.00 (−0.08 to 0.08)   0.97      0.02 (−0.06 to 0.10)     0.63    0.02 (−0.06 to 0.10)     0.63
  Log triglycerides (mmol/L)    854             0.03 (−0.04 to 0.10)    0.43      0.02 (−0.05 to 0.09)     0.54    0.02 (−0.05 to 0.09)     0.64
  Fasting glucose (mmol/L)      855             −0.03 (−0.13 to 0.07)   0.59      −0.01 (−0.11 to 0.09)    0.81    −0.02 (−0.12 to 0.08)    0.68
  Log insulin (mU/L)            854             −0.05 (−0.21 to 0.11)   0.54      −0.12 (−0.26 to 0.01)    0.073   −0.14 (−0.27 to −0.00)   0.045
  Log HOMA-IR                   854             −0.06 (−0.22 to 0.10)   0.46      −0.13 (−0.26 to 0.00)    0.056   −0.14 (−0.27 to −0.01)   0.030

Model 1 is age and sex adjusted.

Model 2 is further adjusted for socioeconomic position and village urbanisation.

Model 3 is adjusted for variables in model 2 plus behavioural risk factors (tobacco and alcohol use; salt and fat consumption; and physical activity level and sedentariness).

Abbreviations: APCAPs, Andhra Pradesh Children and Parents study; BMI, body mass index; BP, blood pressure, IMT, intima-media thickness; LDL, low-density lipoprotein; HDL is High-density Lipoprotein; HOMA-IR, Homeostatic Model Assessment-Insulin Resistance; β (95% CI), beta coefficient and 95% confidence interval

Discussion {#sec012}
==========

In this long-term follow-up of a community-based nonrandomised controlled intervention trial conducted in an area with prevalent undernutrition, provision of supplemental nutrition to pregnant and lactating women (2.09 MJ energy and 20--25 g protein daily) and their offspring until the age of 6 years (1.25 MJ energy and 8--10 g protein daily) was not associated with lower levels of cardiovascular disease risk factors (such as blood pressure, fasting blood lipids and insulin, arterial stiffness, and carotid intima media thickness) among the offspring when they became young adults (mean age 22 years).

Strengths and limitations {#sec013}
-------------------------

The trial was conducted in an area with chronic undernutrition and homogeneous socioeconomic conditions, and women did not consume tobacco, limiting the potential for confounding by maternal and social factors. The subsequent unplanned urbanisation of the study villages, typical of peri-urban sprawls across many LMICs, allowed investigations into the effects of subsequent changes in environment, and make findings generalisable to transitioning areas of other LMICs. The loss to follow-up was relatively low in comparison to similar studies with long-term follow-up, limiting the potential for selection bias \[[@pmed.1003183.ref015]\]. While out-migration for education and employment in young adulthood tends to be high, we may have benefitted from the proximity of the study villages to the urban centre, allowing many people to stay at home and commute to their place of work/study on a daily basis (\>95% still reside in the village of their birth).

There are several limitations to this study that must be acknowledged. First, the villages in the trial were not randomised, raising the possibility of bias from other differences between trial areas. Although the control district was awaiting implementation of the intervention at the time of the trial (and did receive it a few years later in 1992--1993), the intervention district may have may have received the intervention earlier because of some other reason (e.g., political), which could be associated with other differences between the trial areas that could influence health outcomes. Second, we lacked data on compliance with the intervention. Anecdotal reports from investigators involved in the trial suggest that women in the trial were severely undernourished and collection of supplements was high, but the intake was not directly observed. External reports of the ICDS programme suggest that families often share the supplement with other children at home, which could have attenuated the effect of intervention. The lack of data on compliance raises the possibility that the intervention dose may not have been adequate to test the hypothesis robustly. There are no suitable data to guide adequacy of dose of nutritional supplementation, which would be conditional on usual diet from other sources. The ICDS scheme provides approximately 25% of daily energy and protein requirement for the women, and approximately 25% of energy and approximately 50% of protein requirement for the children. The 61 g (95% CI 18--104) difference in birth weight between the trial arms (intervention 2,655 g, control 2,594 g) compares favourably to the mean birth weight difference (41 g; 95% CI 4.7--77.3) reported in a systematic review of trials in which protein-calorie supplementation in pregnancy was directly observed, suggesting that most of the supplement was consumed by the intended beneficiary \[[@pmed.1003183.ref012],[@pmed.1003183.ref013],[@pmed.1003183.ref021]\].

Third, about a third of the cohort could not be followed up. Simple comparison of data collected at the time of first follow-up showed no material difference between those who took part or did not take part in the second or third follow-ups ([Table 1](#pmed.1003183.t001){ref-type="table"}); nevertheless, potential bias in results due to systematic differences in characteristics of those lost to follow-up cannot be ruled out. Fourth, participants and observers who collected field data were not 'blind' to the intervention allocation, which could introduce bias; however, data collection on several outcomes was either automated or processed by those who were blind to the allocation of intervention (e.g., biochemical assays), reducing the likelihood of such bias. Finally, given the age of the participants and the rural study setting, the levels of cardiovascular disease risk factors were relatively low, reducing our ability to detect differences. As rates of cardiovascular disease tend to increase more rapidly with age in India than in many other countries, further follow-up of participants in mid-adulthood will generate more robust data on incident cardiovascular disease \[[@pmed.1003183.ref022]\].

Comparison with previous research {#sec014}
---------------------------------

There are few trials of protein-calorie nutritional supplementation offered to pregnant women and young children with follow-up for cardiovascular risk in adulthood. A cluster randomised trial in The Gambia (28 villages; *N* = 1,317) provided protein-calorie supplements (4.25 MJ of energy and 22 g protein daily) to pregnant (intervention, from 20-week gestation until delivery) or lactating (control, from 20-week gestation until delivery) women, and found no difference in cardiovascular risk factors (blood pressure, body composition, blood cholesterol, and fasting glucose) among offspring when they were aged 11--17 years \[[@pmed.1003183.ref010]\]. Another cluster randomised trial from Guatemala (4 villages; *N* = 429) offered 3.8 MJ of energy and 64 g protein (intervention) or 1.4 MJ of energy (control) supplements twice daily to pregnant and lactating women and children until the age of 7 years and found no difference in cardiovascular risk factors among offspring when they were aged 24 years; however, in subgroup analyses, intervention between the ages of 3 and 6 years was associated with lower fasting glucose and systolic blood pressure, while intervention between birth and 3 years was associated with lower triglyceride and higher high-density lipoprotein cholesterol levels \[[@pmed.1003183.ref011]\]. A trial from rural Bangladesh offered protein-calorie supplementation to pregnant women in early or late pregnancy; at a follow-up conducted at age 4.5 years, early supplementation was associated with lower diastolic blood pressure, but findings in adulthood have not been reported \[[@pmed.1003183.ref023]\].

At the time of the first follow-up of the APCAPs cohort, nutritional supplementation was associated with beneficial effects on several cardiovascular risk factors (i.e., height, arterial stiffness, and insulin resistance) ([Fig 3](#pmed.1003183.g003){ref-type="fig"}) \[[@pmed.1003183.ref012]\]. There are several potential explanations for the difference in findings between the first follow-up (mean age 16 years) and the second or third follow-up (mean age 22 years) reported here. Assuming a true null as the most likely explanation, the positive findings in the first follow-up could have been due to chance (particularly since multiple statistical tests were conducted) or selection bias (participants from the intervention villages with favourable outcomes selectively presenting for examination at the first follow-up). There was weak evidence in favour of the latter hypothesis in the present analyses when the sample was restricted to offspring who were also part of the first follow-up; borderline associations were seen for relevant outcomes, although the overlapping confidence intervals were consistent with no difference between follow-ups (Tables [3](#pmed.1003183.t003){ref-type="table"} and [4](#pmed.1003183.t004){ref-type="table"}). Alternatively, a true effect of the intervention in adolescence may been attenuated over the long-term follow-up due to nutrition or economic transition \[[@pmed.1003183.ref006],[@pmed.1003183.ref007]\], which would support the view that the risk of cardiovascular disease accumulates across the life course \[[@pmed.1003183.ref017]\]. Between 1991 and 2011, the population of study villages increased by 31% (census data), and NTLI and built-up land use (both from remote sensing data) increased by 156% and 196%, respectively, confirming urbanisation of the study villages, which was also found to be associated strongly with cardiovascular risk factors in APCAPs participants \[[@pmed.1003183.ref024]\]. There was some support for this hypothesis from models stratified by urbanisation, which showed weak evidence of the effect of intervention in the least urbanised villages ([S3 Table](#pmed.1003183.s005){ref-type="supplementary-material"}). However, future follow-ups of the participants will be able to provide much greater clarity as the cardiovascular phenotypes mature with age.

![Comparison of findings for selected outcomes in APCAPs participants presenting at first follow-up (FU1, mean age 16 years) and second or third follow-up (FU2/3, mean age 22 years).\
Data shown are means and 95% confidence intervals (blue bars, control; red bars, intervention). \*Geometric mean was used for this variable. APCAPs, Andhra Pradesh Children and Parents study; BP, blood pressure.](pmed.1003183.g003){#pmed.1003183.g003}

Implications {#sec015}
------------

Cardiovascular disease is the leading cause of death and disability in LMICs \[[@pmed.1003183.ref001]\]. The Developmental Origins of Health and Disease hypothesis is of great importance to the unfolding epidemic of cardiovascular disease in many LMICs undergoing nutrition transition, notably countries of South Asia (home to a quarter of the world's population), where up to a quarter of all births are low birth weight \[[@pmed.1003183.ref025],[@pmed.1003183.ref026]\]. These data could not confirm a clear benefit of balanced protein-calorie food supplementation given to undernourished pregnant women and children on cardiovascular disease prevention. Conversely, there was no increase in cardiovascular risk associated with nutritional supplementation, which is important for similar food supplementation programmes in many LMICs that are now concerned about the emerging epidemics of obesity and cardiovascular disease \[[@pmed.1003183.ref027]\]. Given the study limitations and young age of the participants, adverse cardiovascular effects of undernutrition in pregnancy and childhood cannot be ruled out; however, data from trial evidence to date do not support the 'real-world' effectiveness of balanced protein-calorie interventions in pregnancy and/or childhood. There are other potential benefits of improved child nutrition, including respiratory function, cognition, schooling and labour market participation, and reproductive health, which have also been noted in APCAPs \[[@pmed.1003183.ref020]\]. However, until further evidence is available, policy makers should attach limited value to cardiovascular health benefits of maternal and child protein-calorie food supplementation programmes. Meanwhile, further research involving long-term follow-up of participants of intervention studies in which the compliance is monitored is needed to provide more conclusive evidence.

Conclusions {#sec016}
===========

In an area with prevalent undernutrition, protein-calorie food supplementation offered to pregnant women and their offspring in childhood did not lower the offspring's risk of cardiovascular disease in young adulthood. While adverse cardiovascular effects of undernutrition in pregnancy and childhood cannot be ruled out, data from intervention studies to date do not support the real-world effectiveness of balanced protein-calorie interventions in pregnancy and/or childhood.
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Comments from the Academic Editor:

The authors examined the intervention effects of food supplements in a unique trial conducted in three decades ago on profiles of cardiovascular risk factors.

Main comments:

1\. The reviewer initially somehow read as if this study were a community-based cluster randomized controlled trial. It appeared not, where the program did not randomly determine intervention villages and control villages (confirmed in Ref \#12, BMJ article). The non-randomized design should be apparent in Abstract at least. Also, the authors should state the selection criteria for the intervention and no intervention explicitly in the first paragraph of Methods. The authors are encouraged to state clearly, in the abstract and the first paragraph of the Methods, that this study was a community-based non-randomized controlled intervention trial.

2\. The authors found null associations in the primary analysis and described why in Discussion. The authors described the reason that the null finding might be due to the confounding effects of puberty or related factors. This explanation does not make sense. The confounding factor must have occurred before the exposure status was determined. The primary exposure was the intervention to mothers of the participants and to the participants themselves during their childhoods. Puberty factors could not be confounders.

The possible explanations should include the true null, flagging up the possibility of by-chance findings in the previous analysis (BMJ). This current study, showing Table 3 and 4, indicated the selection bias in the previous analysis. The participants selectively showed up the first follow-up and presented favourable outcomes, thereby leading to potentially false-positive results. Also, the previous analysis in BMJ demonstrated a lot of statistical tests and may have substantially raised the likelihood of false-positive findings: the authors should take a fresh look at the results with the null. The authors should suspect such possibilities.

Then, the authors may want to highlight the overall cohort design, given the non-random nature of the exposure and also non-random nature of the responses to the follow-up assessments. It would be difficult to solve, but that should be the point to highlight.

3\. The other possible explanation of the findings was that any positive or adverse effect of the intervention might get diluted over the long-term follow-up given the nutrition or economic transition over time. The authors are encouraged to extract such information from regional data.

4\. The authors should explore the literature and discuss whether the dose levels were sufficient to test the hypothesis. 2.5 MJ of energy intake and 20 g of protein on a single day or over a few months (frequency and duration were not available in this paper actually) may not have been sufficient. The authors should look at the requirement of energy intake and protein intake for pregnant women and the toddlers and compare between those required levels and the provided levels via food supplements.

It would be acceptable that the authors discuss their speculation. However, before the speculation (e.g. puberty effect) without physiologic explanation, the authors seem to have a lot to discuss.

5\. The authors should confirm or disconfirm that the intervention villages were selected because of their socially deprived condition. If so, the authors were testing whether the food supplements let people in deprived villages catch up with those in more affluent villages. This interpretation would be optimistic but fair. The authors may want to touch on this while no randomization was certainly the limitation and to be on emphasis much more.

At the same time, the authors describe the difference between pregnant women in intervention villages and control villages.

Minor comments:

Abstract:

\"cluster trial\" should be \"cluster non-randomized trial\".

Introduction:

\"maybe\" should be \"may be\" in the end of the first paragraph.

The sentence \"We previously reported\...\" should be taken out.

The abstract should include limitations of no randomization or residual confounding and no assessment of compliance with the intervention at least.

Levels of dose, frequency, and duration of the intervention should be available in Abstract.

The conclusion requires revision. The authors should not give a conclusion about what this cohort will have to do: readers may support the promise of this study, but that cannot be the conclusion of this study. The last sentence should be taken out.

Methods:

\"South India\" sounds like a country. \"India\" seems fine.

On the third line of the first paragraph, \"aims\" may sound too odd because the trial started long ago and \"ICDS\" is not clear for readers (and the reviewer) whether it has been lasting for a long time. The authors may want to supplement the information that ICDS is a long-term scheme lasting over decades in India to let the tense make sense.

The authors should clarify the dose frequency and duration of the food supplement, not only the dose levels. Readers could interpret that the investigators had provided just a single package of food.

In the second paragraph of Methods, \"Where individual participant data was\" should be \"Where individual participant data were\".

The authors stated assay quality, but IMT and some of the other measures are not assays. The authors need to rephrase or add sufficient information on a measurement quality for different physiologic measures.

Here are some comments about statistical analyses.

\"We fitted a random-effect at both village and household levels\" is not clear. The authors could assign a random-effect to different parameters in a regression model. Those could be an intercept, a beta coefficient for the binary intervention variable, or both. The current description is not clear. It is highly important to test or describe the variation of effects across villages.

In the statistical section, the authors should explicitly state the need for the statistical adjustment because the trial was susceptible to the bias without randomization.

It would be meaningful to adjust for mediating or intermediary factors. However, the factors the authors describe just after the thought should not be age and sex. They cannot be mediating factors. The authors may want to revise the order of the description would allow an odd interpretation. Alternatively, the authors should state what they think are mediating factors.

Results:

The authors should not abbreviate 2012 into 12.

Table 1 must include information stratified by trial arms: intervention arm and control arm.

Table 2 should have a title of the year or year range of these characteristics and then provide a footnote to explain the timepoint was follow-up measures.

Table 2 has two columns of the sample sizes for different rows. The authors may better drop this. Then, after placing the maximal numbers of participants of the two arms (949 and 877), create the following two columns.

Average % of missing information. Use a superscript to indicate whether the percentages were statistically significantly different between arms.

P values for differences between arms.

In Table 2, the authors may better indicate that \"Resident village urbanization\" and \"Standard of living index\" were both scores based on some index. Otherwise, \"third\" would not make sense.

Table and Figure. For each p-value higher than 0.1, present all the values up to the second decimal place.

Table S3. CIMT needs an explanation for what it stands for.

\"Table S1-4\" is confusing. The authors need to revise this.

The authors use \"wave 1\" or \"wave 2 and 3\", but it is confusing. Descriptions in text and tables are not consistent (sometimes in \"wave\" and other times in years), and it is difficult to read. Then, additionally, in Figure 2, the authors state FU1 and FU2/3. All are confusing. The authors should state \"baseline\", \"follow-up 1\", and \"follow-up 2&3\" throughout in text, tables, and figures. \"Wave\" is not a proper scientific term.

Discussion:

The interpretation of Table 4 in comparison to that of Table 3 should include the selection bias during follow-up. The results in the subset are sensitive to the sampling, which is a study-specific factor. The argument about puberty is little convincing, without any biologically plausible, persuasive arguments. The authors are highly encouraged to take out the argument.

The argument about confounding should be related to the selection of village in regards to the definition of confounding (determinants of exposure). The authors should dig into the selection criteria in details. It is just not convincing (or non-scientific) to speaking about the factors after the intervention as a source of confounding.

The authors should discuss the lack of blinding in this trial for the participants and the assessors. The reviewer understands it would be difficult to achieve, but the limitation should be available in the text.

The authors should describe the policy implications that many interventions may be carried out without any apparent effects on cardiovascular phenotypes.

The lack of assessment of compliance with the intervention seemed to be crucial. The authors\' view was too optimistic. The difference by 61 g in offspring\'s birth weight may have been too small given the absolute levels of birth weights; and also could be by chance, given the history of multiple tests in the prior publications.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from the editors:

Abstract- please provide participant demographics

Abstract- please provide clear number of years of follow-up reported previously and those reported in the current submission

Please revise for clarity and grammar "The levels of cardiovascular risk factors were generally low" and also avoid the use of vague language like generally

Please provide p-values along with 95% CI throughout and within abstract

Abstract methods and findings-last sentence should be a limitation of your methodology

Abstract conclusions should begin with "our results show" or similar

Please place full stop after the reference square brackets

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

Introduction second paragraph- please provide a sentence or two about the previous study before you mention trial and control villages as it is currently not obvious that the previous study was in the same population as in the current submission

Was this trial registered? Please provide details, either way within the methods section

Please provide the study protocol as supplementary information.

Please revise the reporting in accordance with CONSORT guidelines and provide a completed CONSORT checklist as supplementary information

Telangana is a large state, please consider providing a map of the villages in both arms to highlight the spread as well as to indicate which areas have undergone urbanisation

Please clearly provide names and citations of all surveys, questionnaires used in this study. "Tobacco and alcohol were assessed by standard questions" is not sufficient.

Please provide participant demographics in the methods section

Please provide details of ethics approval and informed written consent in the methods section

Discussion- please summarise findings in one paragraph, followed by strengths, limitations and comparison to other studies in the literature

Comments from the reviewers:

Reviewer \#1: This is a statistical review of manuscript PMEDICINE-D-20-00167_R1. The manuscript reports the results of a long-term follow-up of a cluster trial in nutritional supplementation during pregnancy on offspring\'s risk of cardiovascular disease.

The statistical methods are appropriate. The reporting is clear, especially thanks to the use of Tables. I only have two minor comments related to Figure 2. Firstly, the text mentions that height was different in adolescence but height isn\'t reported on Figure 2. Secondly, a legend is missing to distinguish what the blue and red bars represent.

Reviewer \#2: This is an interesting manuscript, describing the follow up of young adults born during a village-based nutrition intervention programme in pregnancy and early childhood in Hyderabad, India. It is an important contribution to the DOHaD field.

Specific comments below largely relate to missing detail about the study design, cohort details etc. that prevent the reader from having a full understanding of the cohort.

Abstract

Background: Developmental Origins of Adult Disease Hypothesis is now more commonly called the Developmental Origins of Health and Disease hypothesis. Also in Background, paragraph 1, and Discussion.

Insert word, \'control of THE cardiovascular disease epidemic ....\'.

Methods and findings, insert word \'further surveys of THE offspring ....\'

Define in abstract, is the 1826 70% of the original number of mother-infant dyads randomized? In the method, it states that 2,964 infants were born into the study (or had a birthweight measured) - 1826/2964 = 61%. This isn\'t clear.

Add some detail to define the low cardiovascular disease risk in the adults (e.g. mean BMI, level of elevated blood pressure).

Background

Missing word \"social disadvantage in THE early years of life .....\"

Methods

Paragraph 2. Further confusion around participant numbers. In paragraph 1, it says that in 2003-5, N=2601 families were contacted (unless I\'m misreading this). But in paragraph 2, it states that N=1165 were followed up in 2003-5. Please make this clear.

What was the difference between Wave 2 and Wave 3? Why were there two separate waves, one year apart? Was there any order in how participants were retraced during these waves?

I note that ten years has passed since wave 2 was complete. Should this be mentioned, e.g. in relation to any further secular trends with respect to CVD risk in India?

Measurements. The reader is referred to two other papers for details on the methodologies used (refs 12 and 14). Ref 12 is the previous follow up study on adolescents, conducted several years earlier. Were all the same interviews used? Is this appropriate, given the differing age/context of the adolescent/young adult groups? Please be specific about which questionnaires/measurements were used as described previously, and which were implemented specifically in this study of adults.

Weight was measure by digital weighing scales (not machine).

For anthropometry, I assume measurements were made in duplicate as you indicated that \"The mean of two anthropometric measurements .....\". But please make this clear. Also, if values were different by \<5cm etc. were both values rejected. Or was this at the point of measurement? Please be clear.

Dietary intake data was collected using a semi-quantitative FFQ: \"A semi-quantitative food frequency questionnaire coupled with customized nutrient databases was used to estimate average daily salt and fat consumption and energy intake; its validation against multiple weighed 24-hour recalls in this setting has been published.\[14\]\". Only salt and fat intakes have been selected for presentation in the current analysis. I think a justification on this point would be helpful. Also, how are salt intakes estimated from a FFQ? Dietary assessment of sodium intake is unreliable at best, even from a full weighted record. A comment on why these two components of dietary intake have been used in the analysis and their reliability, is warranted. Why not intakes of fruits and vegetables? Or sugar sweetened beverages? Would be interesting to look at other components of diet, given the transitional nature of the population.

In addition, Reference 14 is the COHORT profile paper, and does not describe the validation of this tool. Similarly for the statement on physical activity assessment. Please provide the correct, original reference.

Insert word, \"AN enzymatic calorimetric method ......\"

Page 13, the method selected for assessing \'village urbanisation\' (night-time light intensity) has been shown to be valid in a single paper from China. Are there any other internal modes of validation that could be used from within the existing dataset to demonstrate the robustness of this tool within the Indian context?

Ethics. On Page 12 you describe PPI. Where and how was ethical approval obtained for the follow-up survey described here?

Results.

Table 1. Add sex distribution to Table 1. Is the 62% male follow up reported in Table 2 a similar bias (towards males) as in the original birth cohort and in Wave 1?

The intent of this sentence is not clear \"About 20% of the intervention arm participants lived in the least urbanised third of villages, as opposed to 44% from the control arm.\" Or rather, I understand the data as presented in Table 2 - but it\'s not clear if this reflects a bias in rate of urbanisation between the control and intervention villages. I think it would be useful to include this data also in the results - e.g. not participant based, but cluster based. What is the distribution of original village clusters according to the new Resident village urbanisation category? Or are we to assume that participants have not moved - so where they live now, is the same village they lived in when born into the study?

Indeed, in the Discussion, you state that \"then the subsequent attenuation of this difference may have resulted from environmental pressure of urbanisation (which has been disproportionately more in the intervention villages)\" - but this is not clear from the results. Please modify.

Figure 2. I think it would be more helpful to the reader to replace the axes labels of \'FU1\' and \'FU2\' with the age of the participants at follow up.

Discussion

An important omission is the MINIMat trial in Bangladesh, which was a trial of early or usual food supplementation (+ additional micronutrients). Cardiovascular disease risk factors have been measured in the offspring.

<https://www.ncbi.nlm.nih.gov/pubmed/23514767>

<https://www.ncbi.nlm.nih.gov/pubmed/23241449>

Also, an important difference to note between the current Indian trial and those reported from The Gambia and Guatemala (\< Bangladesh should be added) is the timing of intervention; India and Guatemala were interventions given in pregnancy and early childhood; The Gambia and Bangladesh supplements were given in pregnancy only. You should add some consideration of the results obtained from the current study, in relation to these other studies. The Discussion on this point is rather cursory.

I do not follow the statement that \"The linkage to additional data collected during the trial (e.g. nutritional supplement collection and maternal and offspring anthropometrics) was not reliable enough to be incorporated in these analyses\". It is not clear why linkage to these data is not reliable, yet linkage to other participant details (village of birth, dates of birth) is considered reliable. A greater description on the fidelity of the participant information needs to be included in the methods section of the current paper. Is the data presented on birthweights (reported in both the introduction and discussion, published elsewhere? If so, please include a reference. If not, some further information should be included in the Results of the current paper (birthweight by village, sex).

I also don\'t understand this statement: \"We previously analysed the birthweight data from the trial (birthweights were recorded separately for each village, despite unreliable linkage to study participants) and found a difference of 61g (95%CI 18 to 104g) between trial arms (intervention 2655g, control 2594g), which is comparable to birthweight difference (mean difference 41g, 95% CI: 4.7 to 77.3) reported in a systematic review of trials in which protein-calorie supplementation in pregnancy was directly observed, suggesting that this is a minor concern.\[12,13,22\]\". What is a minor concern? This needs restructuring to make it clear what is meant.

Were there any differences in current CVD risk factors according to level of urbanisation of the villages? I believe this could be of value in terms of (i) demonstrating the robustness of the urbanisation tool and (ii) explaining the lack of any associations observed.

Reviewer \#3: PMEDICINE-D-20-00167R1

Impact of nutritional supplementation in pregnancy on offspring\'s risk of cardiovascular disease: long-term follow-up of a cluster trial

Thank you for the opportunity to review this manuscript. This is an interesting and compelling revised paper from a strong research team. The authors assessed whether the provision of supplemental nutrition to undernourished pregnant women and their offspring lowered the offspring\'s risk of cardiovascular disease in young adulthood. The findings of the analyses were null (and the author conducted numerous analyses) but this does not detract from the paper\'s importance. The authors note that rates of cardiovascular disease tend to increase more rapidly with age in India (more so than in many other countries) and so further follow-up of offspring into middle adulthood may yield different results.

This paper is well written and will be of interest to maternal and child health practitioners and researchers interested in early life origins of adult disease.

Minor comments:

1\. The Abstract does not include the primary research question or aim of the study. As written, the research question is not clearly stated but may be gleaned from the middle of the Methods and findings section. The research question is also not clearly stated in the Background section of the manuscript. It would be helpful to include a statement describing the aims of the study just prior to presenting the hypothesis.

2\. The funding disclosures presented at the beginning and end (within the body) of the manuscript are somewhat inconsistent.

3\. There are inconsistent decimal places for estimates and Cis in Tables 3 and 4 and p values presented in supplementary tables.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003183.r003

Author response to Decision Letter 1

30 Apr 2020

###### 

Submitted filename: Response to reviewers_Kinra et al.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003183.r004

Decision Letter 2

Misra

Adya

Senior Editor

© 2020 Adya Misra

2020

Adya Misra

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

22 May 2020

Dear Dr. Kinra,

Thank you very much for re-submitting your manuscript \"Effect of supplemental nutrition in pregnancy on offspring's risk of cardiovascular disease in young adulthood: long-term follow-up of a cluster trial\" (PMEDICINE-D-20-00167R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by xxx reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by May 29 2020 11:59PM.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Title- Please add India to the title. Could you please also just say \"follow-up of a cluster trial\".

The original manuscript document instead of the revised document has been included in the manuscript PDF, please remove the original manuscript copy within editorial manager

Author summary- please add bullet points

Line 66,67 needs revision, since you are presenting results from a non-randomised study?

Lines 75,76- could you revise for clarity? The use of "who" twice is a bit unclear

Author summary lines 78-79 should be tempered, as there are several confounders. Perhaps you can add "our results suggest..." or similar?

Line 80- "cannot" is rather emphatic, please tone down to "should not". This part of the summary should be revised to indicate that an intervention to the limited time segments (just during a pregnancy period and just after giving birth) was insufficient.

We do not require a patient and public involvement section. However, if you wish to include any of these details within the methods section please do so

Please can you confirm that the included map is free from any copyright restrictions?

Please state within the methods section if any changes were made to the study protocol and provide reasons for the same

Could you please remove page numbers in the CONSORT checklist and replace with section and paragraph numbers. Please also rename the file to state that it is the CONSORT checklist.

Implications

Implications should include the need for monitoring, in general, compliance of program participants with an intervention program.

It is possible that a lack of monitoring would make an effective intervention meaningless. This study is in line with it.

Table 2-The authors should create one more column of p-values from the test comparing intervention groups and control groups for each variable.

Or I would suggest revise this column to include p-values from the comparison between two groups. It may be ok to put a table footnote that there was no significant difference in degrees of missing information between the two groups.

Village urbanisation score This variable clearly showed the difference between the intervention group and control group. The authors should highlight it.

Table 3- I would suggest to create two columns for Model 1, Model 2, and Model 3 each, putting effect measures in one column and p-values in the other column in each. "p=0.xx"look too messy.

Fig3 Bar charts are not good choice. A bar indicates a range from 0 to some positive value. But none of the variables in Fig 3 can be zero. The authors should use diamonds or circules as the best point estimates and 95% confidence intervals.

Comments from Reviewers:

Reviewer \#1: The authors have satisfactorily addressed my comments.

Reviewer \#2: The authors have adequately addressed all the comments made by both myself and the other reviewers and I believe this paper is now suitable for publication.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003183.r005

Author response to Decision Letter 2

9 Jun 2020

###### 

Submitted filename: Response to editors after further revision.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003183.r006

Decision Letter 3

Misra

Adya

Senior Editor

© 2020 Adya Misra

2020

Adya Misra

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

16 Jun 2020

Dear Dr. Kinra,

On behalf of my colleagues and the academic editor, Dr. Fumiaki Imamura, I am delighted to inform you that your manuscript entitled \"Effect of supplemental nutrition in pregnancy on offspring's risk of cardiovascular disease in young adulthood: long-term follow-up of a cluster trial from India\" (PMEDICINE-D-20-00167R3) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: I have read the journal's policy and the authors of this manuscript have the following competing interests: GDS is a member of the Editorial Board of *PLOS Medicine*.
